Immunome, Inc. Tech Stack
Clinical-stage oncology company advancing targeted cancer therapies and ADC programs
Immunome is a public clinical-stage oncology company with a portfolio of targeted therapies across Phase 3, Phase 1, and preclinical stages. The tech stack reveals a company mid-transformation: core scientific tools (SAS, MATLAB, LC-MS) support drug discovery and pharmacokinetics, while enterprise infrastructure (Veeva, Medidata, ServiceNow, NetSuite ERP adoption) signals preparation for scale and regulatory submission. Hiring velocity is accelerating across operations, data, and research—matched by active projects spanning protein engineering, ADC purification at GMP scale, and commercial readiness integration.
Tech Stack 27 technologies
What Immunome, Inc. Is Building
◆Challenges
- Developing next generation adc therapeutics
- Ensuring timely safety reporting
- Complex regulatory submissions
- Rapid integration of enterprise systems
- Scaling purification processes to gmp
- Technology transfer to cdmo
- Regulatory compliance for mab purification
- High-throughput recombinant protein production
- Security incident response
- Seamless data-driven hcp experience
▲Active Projects
- Preclinical discovery of novel adc technologies
- Open enrollment project management
- Protein inventory management
- Protein engineering and discovery workflows
- Commercial readiness integration
- Enterprise analytics expansion
- Adc purification process optimization
- Continuous improvement of itsm processes
- Infrastructure planning and lifecycle management initiatives
- High-throughput recombinant protein production
Hiring Activity
Department
Seniority
Notable leadership hires: Global Regulatory Lead, Market Access Director